T7 RNA Polymerase Variants for Improved Capping and Lower dsRNA
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Bacteriophage T7 RNA polymerase produces RNA transcripts with low 5' end capping efficiency and generates undesirable double-stranded RNA (dsRNA) contaminants due to aberrant activity, leading to immune-stimulatory effects.
Innovation Solution
Development of T7 RNA polymerase variants with specific amino acid substitutions at positions D351, K387, N437, and optionally E350 or D653, enhancing capping efficiency and reducing dsRNA formation during in vitro transcription.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If wild-type T7 RNA polymerase is used for in vitro transcription, then the transcription reaction is simple and fast, but it produces dsRNA contaminants and has low 5' end capping efficiency
Solution Approach 1:
The patent applies parameter changes by introducing specific amino acid substitutions at positions D351, K387, N437, E350, and/or D653 in the T7 RNA polymerase sequence. These sequence parameter modifications alter the polymerase's biochemical properties to reduce dsRNA formation and improve cap analog binding affinity, thereby resolving the contradiction between simple transcription and high capping efficiency.
2Reliability
If wild-type T7 RNA polymerase is used, then the transcription process is straightforward, but it requires high cap analog concentrations to achieve acceptable capping efficiency
Solution Approach 1:
The patent modifies the T7 RNA polymerase sequence parameters through amino acid substitutions at key positions (D351, K387, N437, E350, D653), which enhances the polymerase's binding affinity for cap analogs. This parameter change allows the system to achieve high capping efficiency at lower cap analog concentrations, resolving the contradiction between capping efficiency and cap analog quantity required.
3Productivity
If wild-type T7 RNA polymerase is used, then the transcription reaction is fast and simple, but it produces aberrant transcripts that stimulate immune responses
Solution Approach 1:
The patent introduces specific amino acid substitutions (D351, K387, N437, E350, D653) that modify the T7 RNA polymerase's transcriptional fidelity and aberrant activity parameters. These changes reduce the production of immune-stimulatory dsRNA and aberrant transcripts while maintaining high transcription speed, thus resolving the contradiction between productivity and harmful immune-stimulatory effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The variants improve co-transcriptional capping efficiency and reduce dsRNA contamination, increasing RNA yield and fidelity while allowing lower cap analog concentrations, thus enhancing the quality and purity of RNA products.
Implementation Method 1
catalyzes the formation of phosphodiester bonds between ribonucleoside triphosphates
Implementation Method 2
the polymerase has low binding affinity for the cap analog(s)
Data Source
AI summary
RNA polymerase variants enable high efficiency transcription of RNA. In Yield some embodiments, the RNA polymerase variants enable RNA transcription with high capping efficiency and/or low levels of double-stranded RNA contamination.